Valtecne (VLT) investor relations material

Executive summary

• Consolidated revenues reached €19.6M in H1 2026, up 0.8% year-over-year, reflecting stable performance in a selective market.

• EBITDA grew by 8.1% to €5.0M, with margin improvement to 24.2% of production value; adjusted EBITDA was €5.6M, up 3.2%.

• Net profit rose 17.6% to €2.3M, with a positive net financial position of €2.14M.

• The Medical segment saw a slight revenue decline (-2.5%) due to timing of revenue recognition, while Industrial grew 10.9%.

• Major share acquisition completed post-period, marking a new strategic phase.

Financial highlights

• Revenues: €19.6M (+0.8% YoY); Value of production: €20.5M (+1.0% YoY).

• EBITDA: €5.0M (+8.1% YoY); Adjusted EBITDA: €5.6M (+3.2% YoY); EBITDA margin: 24.2%.

• EBIT: €3.3M (+12.4% YoY); EBIT margin: 16.2%.

• Net profit: €2.3M (+17.6% YoY); Net profit margin: 11.7%.

• Net financial position: €2.14M (improved from €1.83M at 2025 year-end); shareholders' equity: €28.6M.

• Dividend payout of €0.10/share, totaling €0.7M.

Outlook and guidance

• Order backlog remains solid, supporting positive prospects for H2 2026.

• Management expects FY26 volumes to slightly contract but profitability to remain in line with FY25.

• Strategic focus remains on expanding the Medical segment and optimizing Industrial operations.

• Industrial and higher value-added segments, especially dental, are experiencing favorable growth.